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Introduction and rationale
Peripheral arterial disease (PAD) is categorised by stenotic 
or occlusive atherosclerotic lesions in the arteries that supply 
the legs, limiting blood flow.1 The incidence of PAD 
increases with advancing age and large-scale global esti-
mates demonstrate that it affects 1 in 10 over the age of 
70 years and 1 in 6 over the age of 80 years.2 The main symp-
tomatic manifestation of PAD is intermittent claudication 
(IC), which is a reproducible ambulatory lower limb muscle 
pain, relieved by rest, that occurs due to an oxygen supply 
and demand imbalance.3,4
IC can impede daily activities, functional capacity and 
quality of life (QoL) while also carrying an increased mortal-
ity risk.3–7 These impediments can cause a cycle of disabil-
ity; as pain increases with walking, patients walk for shorter 
distances, leading to muscle atrophy and a further reduced 
walking capacity.8
First-line treatment for IC is a supervised exercise pro-
gramme (SEP) which ideally includes 2 h of supervised exer-
cise per week for 12 weeks, whereby patients are encouraged 
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to walk to the point of maximal pain.9 There is overwhelm-
ing evidence that exercise programmes are of significant 
benefit for improving walking time and distance in those 
with IC, as demonstrated in a recent Cochrane review.10 This 
benefit is obtainable from low or higher intensity supervised 
walking or differing modes of exercise (e.g. cycling).11,12
Despite its benefits, a recent systematic review found that 
approximately 1 in 3 IC patients screened were suitable and 
willing to join a SEP, suggesting it is underutilised.13 
Furthermore, research has shown that not all NHS Vascular 
units have access to a SEP.14 Consequently, there has been an 
increased interest in home-based exercise programmes 
(HEPs). A recent Cochrane review in 2018 considered super-
vised exercise versus home-based exercise versus walking 
advice for IC which demonstrated that HEPs were inferior to 
SEPs for improving walking distance at 3 months.15 The HEP 
group also did not show significant improvements in maxi-
mum walking distance (MWD) when compared to the walk-
ing advice group. However, the differences in increased 
MWD elicited by the SEP group was 210 m versus the walk-
ing advice group, but lower at 120 m versus the HEP group, 
suggesting HEPs may be more beneficial than walking 
advice.15 Another systematic review published in 2013 dem-
onstrated that there was low quality, preliminary evidence 
that HEPs can provide an improvement in walking capacity 
and QoL in IC patients.16 However, the evidence also sug-
gests that these improvements may be inferior to those seen 
with SEPs. The review concluded that more robust trials are 
required to build the evidence base for HEPs in patients with 
IC, which should have prompted further research.16 Therefore, 
this protocol, written in accordance with PRISMA-P guide-
lines,17 proposes to update the previous systematic review. 
The aim of this updated review is to consider the effective-
ness of HEPs as a treatment option for improving walking 
distance or time in patients with IC.
Our proposed review differs to the aforementioned 
Cochrane review as this only included studies that had a SEP 
as one comparator arm, whereas we will include studies that 
compare a HEP with any comparator arm, such as walking 
advice and a no exercise control, rather than a SEP. In addi-
tion, we will consider changes in physical activity as an out-
come measure and identify the components of an effective 
intervention to help provide guidance on an effective HEP 
programme that can be used in practice. Finally, the search 
for the Cochrane review was concluded in December 2016, 
meaning that any articles published after this date will not be 
encompassed in their results.
Methods
Search strategy and inclusion criteria
Prospective non-randomised and randomised controlled tri-
als (RCTs) that consider the effect of a home-based exercise 
regimen versus a comparator arm (SEP, exercise advice or no 
exercise control) on walking distance or time for patients 
with IC will be included. In contrast to the previous review, 
in order to maximise data, studies that include other PAD 
subgroups (i.e. asymptomatic or atypical leg pain) in addi-
tion to IC will be included, only if the data on the IC sub-
group can be obtained. Other PAD subgroups will not be 
included as SEPs are only currently recommended for the 
treatment of IC, with HEPs being a potential alternative.
The HEP intervention will include structured advice to 
increase physical activity by guiding patients in terms of fre-
quency, intensity and/or duration rather than basic advice ‘to 
go home and walk’. Patients may be monitored via use of 
pedometers, accelerometers, physical activity monitors, 
exercise diaries or any combination thereof. Encouragement 
can also be provided by regular supportive interactions, such 
as telephone calls or visits either at home or at the research 
centre. However, in line with previous research, active moni-
toring for HEPs will be limited to a maximum of two interac-
tions per week.18 For comparator arms, SEPs will be defined 
as any actively supervised exercise regime for the treatment 
of IC regardless of the duration, frequency or intensity of the 
programme. The exercise advice group will be defined as 
patients who are encouraged to walk more at home, without 
receiving specific recommendations for an exercise regimen. 
The no exercise control group will consist of those who 
either receive no exercise-specific advice or are told to main-
tain their usual physical activity levels.
The original search strategy searched four databases for 
terms including ‘peripheral arterial disease’ [AND] ‘self-
management’ [AND] ‘exercise’ and yielded 311 results. The 
proposed search will build on this and include five databases 
(CINAHL, PEDro, Medline, EMBASE and Cochrane 
CENTRAL) and a wider range of search terms (draft search 
included in Supplemental Appendix 1). Although it was 
included in the previous review, the PsychINFO database 
will not be searched as it was not considered an appropriate 
for the context of the current review. In addition, trial regis-
ters such as clinicaltrials.gov and the web of science confer-
ence proceedings will be searched and authors of any relevant 
protocols and conference abstracts will be contacted to 
obtain study outcome reports where possible. As the pro-
posed search differs from that of the original review, no date 
restrictions will be applied to ensure that any studies not 
encompassed in the previous search will be retrieved and 
only studies published in the English language will be 
included.
Data management, selection and collection 
process
Titles and abstracts identified by the database search will be 
interrogated for potential eligibility by two independent 
reviewers. The full-text of these potentially eligible studies 
will be obtained and further interrogated for inclusion. 
Reference lists of any screened full-texts will also be hand 
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searched for other relevant papers. Any disagreement 
between the two reviewers in terms of inclusion will be 
resolved by consensus with a third.
Data extraction will then be performed by two reviewers 
using a standardised form, which will then be inputted and 
managed using a Microsoft Excel database (Microsoft, 2010, 
Redmond, WA, USA). Data regarding search hits, duplicates 
and included and excluded (with explanation) studies will 
also be recorded in the database to allow creation of the 
PRISMA flow diagram.19 Data extraction will include study 
characteristics (country, design and appropriate information 
to assess the quality of the study), sample size and descrip-
tion, a description of the intervention and control conditions, 
outcome measures, length of follow-up and main findings 
related to outcome measures (sample data extraction sheet 
shown in Supplemental Appendix 2).
Outcome measures
The primary outcome will be objectively measured (via 
either treadmill or corridor-based tests) MWD or maximum 
walking time (MWT). Secondary outcomes measures (where 
reported) will be objectively measured pain-free walking 
distance (PFWD) or pain-free walking time (PFWT), health-
related QoL, assessed using validated disease specific or 
generic scales such as the short-form 36 (SF-36) and changes 
in physical activity, either objectively measured or self-
reported. PFWD/PFWT will be defined as the time or dis-
tance where the patient first experiences leg pain during the 
walking test and MWD/MWT will be defined as the time or 
distance at which the patient can no longer continue walking 
due to maximal pain. These outcomes have been selected as 
the previous review demonstrated that there was low-level 
evidence to suggest that HEPs can improve walking capacity 
and QoL in patients with IC, while physical activity has also 
been selected to establish any potential lifestyle changes as a 
result of the HEP.
Risk of bias and rating the quality of evidence
Risk of bias in individual studies will be assessed using the 
Cochrane collaboration tool which includes six domains.20 
Information will be extracted from each study and a judge-
ment made for each domain that will be either ‘high risk’, 
‘low risk’ or ‘unclear risk’ if sufficient detail is not provided. 
In the case of ‘unclear risk’ study, authors will be contacted 
for more information. A justification statement will be given 
for each risk domain, describing the methods utilised in each 
study, using verbatim quotes where possible as recom-
mended in the Cochrane handbook.20 Two independent 
reviewers will assess the risk of bias and discuss any disa-
greements. Consensus with a third reviewer will be sought 
should an agreement not be reached.
Quality of evidence will be assessed by two independent 
reviewers using the GRADE approach.21 Initial assessment 
will be made based on design and will then be revised 
(upgraded or downgraded) based on the following criteria: 
risk of bias, inconsistency, indirectness, imprecision and 
publication bias.21 Quality level is then categorised based on 
this revision as high (very confident that the true effect lies 
close that of the estimate of effect), moderate (true effect is 
likely to be close to the estimate of the effect, but may be 
substantially different), low (true effect may be substantially 
different from the estimate of effect) and very low (true 
effect is likely to be substantially different from the estimate 
of effect).21
Data analysis and synthesis
To increase the scope of this systematic review, both RCTs 
and non-RCTs will be included and a narrative synthesis of 
non-RCTs produced. In an attempt to overcome the hetero-
geneity that previously precluded it, we propose to undertake 
a meta-analysis using only the included RCTs. Meta-analysis 
will be performed using Review Manager 5 (RevMan 2014), 
to produce forest plots with an overall effect estimate and 
associated 95% confidence intervals. An element of hetero-
geneity is likely across studies due to possible differences in 
the types of interventions and outcomes reported.22 
Substantial heterogeneity will be considered present if the I2 
is >50% and the p value for the Chi2 test is <0.10. Should 
substantial heterogeneity not be present, data will be pooled 
and a meta-analysis performed using a fixed-effects model. 
However, if substantial heterogeneity is found, this will be 
evaluated based on the cause and one of two courses of 
action will be taken. Should it be felt that the heterogeneity 
is unexplained, a meta-analysis will be performed using a 
random-effects model as this considers heterogeneity in the 
effect estimate.22 It does not however remove it and the het-
erogeneity will be considered during interpretation of results. 
Furthermore, should meta-analysis be deemed appropriate, 
the robustness of the findings will be determined via sensi-
tivity analysis. For this, we will alter the dataset by removing 
RCTs of lower quality based on the risk of bias assessment 
and repeating the analysis.23 If the analysis is robust, the 
change in outcomes should be minimal.23
However, should heterogeneity be caused by an identifi-
able reason, such as clear differences between interven-
tions, data will not be pooled for meta-analysis as this may 
provide misleading results.22 In this case, as with the previ-
ous review, a narrative approach will be used and between-
group effect sizes for MWD or MWT calculated.16
Results will be presented as a head-to-head analysis of the 
effectiveness of HEPs versus each comparator arm. It is 
therefore anticipated that results will be presented as HEPs 
versus SEPs, HEPs versus exercise advice and HEPs versus 
no exercise control. In addition, should adequate data be 
available, subgroup analysis of HEPs will be performed on 
the basis of monitoring, gender, comorbidities (such as dia-
betes and coronary heart disease) and disease severity 
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(categorised by ankle brachial pressure index or Rutherford/
Fontaine classification). This will allow us to identify the 
effect of these factors on outcomes follow HEPs.
We will also provide a narrative description of the compo-
nents of effective HEP interventions, such as the volume of 
exercise or the use of dietary and lifestyle advice and psy-
chological components. Effective HEP interventions will be 
identified as those that induce a significantly greater change 
(p ≤ 0.05) for at least one outcome, when compared with the 
exercise advice or no exercise control comparator groups. 
For trials comparing SEP and HEP, without a third no exer-
cise control or exercise advice comparator group, the HEP 
intervention will be considered effective if it induces a sig-
nificant positive change from baseline (p  ≤ 0.05).
Discussion and conclusion
This article proposes an update of a 2013 systematic review 
which considered the role of HEPs for patients with IC. The 
previous review should have prompted further research by 
suggesting more robust trials are needed to build an appro-
priate evidence base for HEPs in IC.16 This renewed evi-
dence base was evaluated in an updated Cochrane review 
which demonstrated that HEPs were markedly inferior to 
SEPs for improvements in MWD and PFWD at 3 months.15 
Our proposed review differs from this Cochrane update as it 
will include, rather than exclude, studies that use a no exer-
cise control group, thus evaluating the benefit of HEPs ver-
sus control. Although guidelines do recommend walking 
advice in the treatment of PAD, meaning studies including 
no exercise advice may not exist, a preliminary search has 
revealed at least two potentially eligible articles that include 
groups of this nature.
There are possible limitations that may occur within the 
proposed review. The original review published in 2013 
noted that heterogeneity precluded meta-analysis, which 
may be the case for the proposed review. Although we will 
still include both randomised and non-randomised trials to 
enhance the scope of this review, we aim to overcome the 
problem of heterogeneity by only including RCTs in the pro-
posed meta-analysis.
In addition, as further research was only prompted by the 
previous review in 2013, it is possible that some trials are 
still ongoing or data are yet to be published. Although we 
hope to minimise this possibility by searching clinical trial 
registers and contacting authors for study outcomes where 
possible, we cannot eradicate it as some trials may not be 
registered.
Overall, this proposed review seeks to consider the 
renewed evidence base for the effectiveness of HEPs as an 
alternative treatment option for IC, by performing an 
update of a previous review and furthering it by performing 
a meta-analysis of the included RCTs, based on heteroge-
neity. The inclusion of both randomised and non-ran-
domised trials, while also performing a meta-analysis of 
RCTs, will provide a comprehensive and complete over-
view of the evidence base for HEPs, which can aid clini-
cians in the management of their patients. In addition, by 
outlining the effective components of an intervention, this 
review can aid exercise professionals to design and imple-
ment a structured, evidence-based HEP for those IC patients 
unable to attend SEP.
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